By having the ability to bind BCMA and CD38 simultaneously, TCE’s avidity to bind to the target tumor is advantageous and was associated with low on-target, off-tumor activity compared with the combination of the CD38-specific and BCMA-specific TCEs constructed with the same binding domains. The gene discussed is TNFRSF17; the disease is neoplasm.